Compared to Estimates, DuPont de Nemours (DD) Q3 Earnings: A Look at Key Metrics
Werte in diesem Artikel
For the quarter ended September 2024, DuPont de Nemours (DD) reported revenue of $3.19 billion, up 4.4% over the same period last year. EPS came in at $1.18, compared to $0.92 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.2 billion, representing a surprise of -0.22%. The company delivered an EPS surprise of +13.46%, with the consensus EPS estimate being $1.04.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how DuPont de Nemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Electronics & Industrial: $1.55 billion compared to the $1.55 billion average estimate based on three analysts. The reported number represents a change of +13.4% year over year. Net Sales- Corporate & Other: $259 million versus $257.21 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.5% change. Net Sales- Water & Protection: $1.38 billion versus $1.39 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change. Operating EBITDA- Electronics & Industrial: $467 million versus $454.59 million estimated by three analysts on average. Operating EBITDA- Corporate & Other: $26 million versus the three-analyst average estimate of $16.50 million. Operating EBITDA- Water & Protection: $364 million versus $346.08 million estimated by three analysts on average. View all Key Company Metrics for DuPont de Nemours here>>>Shares of DuPont de Nemours have returned -4.8% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DuPont de Nemours, Inc. (DD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf DuPont de Nemours
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DuPont de Nemours
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu DuPont de Nemours
Analysen zu DuPont de Nemours
Datum | Rating | Analyst | |
---|---|---|---|
04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
12.10.2018 | DowDuPont buy | Deutsche Bank AG | |
29.03.2018 | DowDuPont Outperform | BMO Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC | |
12.09.2017 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
31.05.2017 | Dow Chemical Market Perform | Cowen and Company, LLC | |
26.04.2017 | DuPont (E I DuPont de Nemours and Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
05.01.2009 | Dow Chemical verkaufen | Euro am Sonntag | |
11.04.2007 | Dow Chemical verkaufen | Hamburger Sparkasse | |
03.02.2006 | Update Rohm and Haas Co.: Reduce | UBS | |
07.07.2005 | Update Rohm and Haas Co.: Sell | Longbow |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DuPont de Nemours nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen